Meeting
2023 ASCO Annual Meeting
The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.
Authors
Irene L.M. Reijers
Netherlands Cancer Institute, Amsterdam, Netherlands
Irene L.M. Reijers , Itske Fraterman , Petros Dimitriadis , Annegien Broeks , Maria Gonzalez , Alexander M. Menzies , Ellen Kapiteijn , Astrid Aplonia Maria Van Der Veldt , Karijn Suijkerbuijk , Geke Hospers , Georgina V. Long , Christian U. Blank , Lonneke van de Poll-Franse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02977052
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9558)
DOI
10.1200/JCO.2023.41.16_suppl.9558
Abstract #
9558
Poster Bd #
321
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
First Author: Milton Jose De Barros E Silva
Poster
2022 ASCO Annual Meeting
The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.
First Author: Irene L.M. Reijers
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis
Poster
2020 ASCO Virtual Scientific Program
Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.
First Author: Irene L.M. Reijers